ID   HL60/AR
AC   CVCL_WI27
SY   HAR
DR   cancercelllines; CVCL_WI27
DR   Wikidata; Q94211961
RX   PubMed=24368162;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_2038; 5-azacytidine (5-azaC).
CC   Sequence variation: Gene deletion; HGNC; HGNC:11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Caution: Not to be confused with HL-60/AR (Cellosaurus=CVCL_WR44) which is an anthracycline resistant subline of HL-60.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C7961; Adult acute myeloid leukemia with maturation
DI   ORDO; Orphanet_98834; Acute myeloblastic leukemia with maturation
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0002 ! HL-60
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 14-08-25; Version: 13
//
RX   PubMed=24368162; DOI=10.1016/j.exphem.2013.12.004;
RA   Sripayap, Piyanuch
RA   Nagai, Tadashi
RA   Uesawa, Mitsuyo
RA   Kobayashi, Hiroyuki
RA   Tsukahara, Tomonori
RA   Ohmine, Ken
RA   Muroi, Kazuo
RA   Ozawa, Keiya
RT   "Mechanisms of resistance to azacitidine in human leukemia cell
RT   lines.";
RL   Exp. Hematol. 42:294-306.e2(2014).
//